MX2020001157A - Compuestos y analogos de 1-heterociclil isocromanilo para el tratamiento de trastornos del sistema nervioso central (snc). - Google Patents

Compuestos y analogos de 1-heterociclil isocromanilo para el tratamiento de trastornos del sistema nervioso central (snc).

Info

Publication number
MX2020001157A
MX2020001157A MX2020001157A MX2020001157A MX2020001157A MX 2020001157 A MX2020001157 A MX 2020001157A MX 2020001157 A MX2020001157 A MX 2020001157A MX 2020001157 A MX2020001157 A MX 2020001157A MX 2020001157 A MX2020001157 A MX 2020001157A
Authority
MX
Mexico
Prior art keywords
sup
compounds
isochromanyl
heterocyclyl
analogs
Prior art date
Application number
MX2020001157A
Other languages
English (en)
Inventor
G Hanania Taleen
ALEXANDROV Vadim
L Spear Kerry
Aaron Powell Noel
Glyn Jones Philip
Xie Linghong
Original Assignee
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunovion Pharmaceuticals Inc filed Critical Sunovion Pharmaceuticals Inc
Publication of MX2020001157A publication Critical patent/MX2020001157A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen compuestos de la Fórmula (I): (ver Fórmula) y sales farmacéuticamente aceptables de los mismos, en donde A, Ra, R1, R2, R3, R4, R6, w y n1 se definen y describen en la presente; composiciones de los mismos; y métodos de uso de los mismos. Estos compuestos son útiles para tratar una variedad de trastornos neurológicos y psiquiátricos, tales como los descritos aquí.
MX2020001157A 2015-02-11 2016-02-11 Compuestos y analogos de 1-heterociclil isocromanilo para el tratamiento de trastornos del sistema nervioso central (snc). MX2020001157A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562115064P 2015-02-11 2015-02-11
PCT/US2016/017539 WO2016130796A1 (en) 2015-02-11 2016-02-11 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders

Publications (1)

Publication Number Publication Date
MX2020001157A true MX2020001157A (es) 2022-05-27

Family

ID=55456908

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020001157A MX2020001157A (es) 2015-02-11 2016-02-11 Compuestos y analogos de 1-heterociclil isocromanilo para el tratamiento de trastornos del sistema nervioso central (snc).
MX2017010363A MX371404B (es) 2015-02-11 2016-02-11 Compuestos y analogos de 1-heterociclil isocromanilo para el tratamiento de trastornos del sistema nervioso central (snc).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2017010363A MX371404B (es) 2015-02-11 2016-02-11 Compuestos y analogos de 1-heterociclil isocromanilo para el tratamiento de trastornos del sistema nervioso central (snc).

Country Status (21)

Country Link
US (4) US9856238B2 (es)
EP (2) EP3256466B9 (es)
JP (3) JP6657241B2 (es)
KR (1) KR102601972B1 (es)
CN (2) CN111925360B (es)
AU (1) AU2016219253C1 (es)
CA (1) CA2976095C (es)
DK (1) DK3256466T3 (es)
EA (1) EA201791804A1 (es)
ES (2) ES2967643T3 (es)
HU (1) HUE058698T2 (es)
IL (1) IL253914B (es)
MX (2) MX2020001157A (es)
MY (1) MY188160A (es)
NZ (1) NZ735011A (es)
PH (1) PH12017501422A1 (es)
PL (1) PL3256466T3 (es)
PT (1) PT3256466T (es)
SG (2) SG11201706515QA (es)
UA (1) UA122222C2 (es)
WO (1) WO2016130796A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016219247B2 (en) * 2015-02-11 2020-08-13 Pgi Drug Discovery Llc Fused dihydro-4H-pyrazolo[5,1-C][1,4]oxazinyl compounds and analogs for treating CNS disorders
EP3256466B9 (en) * 2015-02-11 2022-07-27 Sunovion Pharmaceuticals Inc. 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
EP3490607A4 (en) 2016-07-29 2020-04-08 Sunovion Pharmaceuticals Inc. COMPOUNDS AND COMPOSITIONS, AND USES THEREOF
WO2018023072A2 (en) 2016-07-29 2018-02-01 Sunovion Pharmaceuticals, Inc. Compounds and compositions and uses thereof
US11266633B2 (en) 2017-06-30 2022-03-08 Chase Therapeutics Corporation NK-1 antagonist compositions and methods for use in treating depression
JP7191085B2 (ja) 2017-08-02 2022-12-16 サノビオン ファーマシューティカルズ インク イソクロマン化合物およびその使用
MX2021010880A (es) 2019-03-14 2022-01-18 Sunovion Pharmaceuticals Inc Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3438995A (en) 1968-01-08 1969-04-15 Melville Sahyun Diazaheterocyclic substituted benz-oxaheterocyclic compounds
US5621133A (en) 1989-05-31 1997-04-15 Deninno; Michael P. Dopamine agonists
US4963568A (en) 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
IE73232B1 (en) * 1990-05-25 1997-05-21 Akzo Nv Isochromane derivatives
US5238939A (en) * 1990-05-25 1993-08-24 Akzo N.V. Isochromane derivatives
CA2336254A1 (en) 1998-06-30 2000-01-06 Daniel James Koch 5-ht1f agonists
SE9902267D0 (sv) 1999-06-16 1999-06-16 Astra Ab New compounds
JP2005510518A (ja) * 2001-11-08 2005-04-21 セプラコール， インク． シタロプラムのデスメチル代謝産物及びジデスメチル代謝産物の濃縮された鏡像異性体を用いてうつ病及び他のｃｎｓ障害を治療する方法
KR100965190B1 (ko) * 2004-12-21 2010-06-24 에프. 호프만-라 로슈 아게 크로만 유도체 및 중추 신경계 장애의 치료에서 그의 용도
CA2605587A1 (en) 2005-04-22 2006-11-02 Wyeth Chromane and chromene derivatives and uses thereof
CA2637261A1 (en) * 2006-01-27 2007-08-02 F. Hoffmann-La Roche Ag Use of 2-imidazoles for the treatment of cns disorders
KR101103118B1 (ko) 2007-11-02 2012-01-04 동아제약주식회사 신규한 1,3-디히드로-5-이소벤조퓨란카르보니트릴 유도체 화합물 및 이를 함유하는 조루증 치료용 약학조성물
SG181498A1 (en) 2009-12-04 2012-07-30 Sunovion Pharmaceuticals Inc Multicyclic compounds and methods of use thereof
EP2683710B1 (en) 2011-03-10 2017-07-19 Boehringer Ingelheim International GmbH Soluble guanylate cyclase activators
AR090557A1 (es) 2012-04-02 2014-11-19 Orion Corp DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2
CA2896871A1 (en) * 2012-12-31 2014-07-03 Kerry L. Spear Heterocyclic compounds and methods of use thereof
EP3256466B9 (en) * 2015-02-11 2022-07-27 Sunovion Pharmaceuticals Inc. 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders

Also Published As

Publication number Publication date
KR20170129730A (ko) 2017-11-27
US20170001987A1 (en) 2017-01-05
EP3256466B9 (en) 2022-07-27
US20180093974A1 (en) 2018-04-05
PL3256466T3 (pl) 2022-05-23
ES2967643T3 (es) 2024-05-03
CN111925360B (zh) 2024-03-22
EP3256466B1 (en) 2022-04-06
EP4046995A1 (en) 2022-08-24
PH12017501422A1 (en) 2018-03-19
NZ735011A (en) 2023-07-28
EP4046995C0 (en) 2023-09-13
JP7023994B2 (ja) 2022-02-22
HUE058698T2 (hu) 2022-09-28
CA2976095A1 (en) 2016-08-18
JP2022065050A (ja) 2022-04-26
IL253914B (en) 2021-09-30
US9856238B2 (en) 2018-01-02
MX371404B (es) 2020-01-29
EA201791804A1 (ru) 2018-02-28
MY188160A (en) 2021-11-24
IL253914A0 (en) 2017-10-31
DK3256466T3 (da) 2022-05-02
SG10201806809QA (en) 2018-09-27
US20220185799A1 (en) 2022-06-16
CN107531674B (zh) 2020-07-31
US11192885B2 (en) 2021-12-07
JP2018505205A (ja) 2018-02-22
KR102601972B1 (ko) 2023-11-13
JP2020079282A (ja) 2020-05-28
AU2016219253B2 (en) 2020-10-01
US10336732B2 (en) 2019-07-02
CN111925360A (zh) 2020-11-13
AU2016219253A1 (en) 2017-09-21
EP3256466A1 (en) 2017-12-20
CN107531674A (zh) 2018-01-02
EP4046995B1 (en) 2023-09-13
US20190389845A1 (en) 2019-12-26
ES2911910T9 (es) 2022-08-12
JP6657241B2 (ja) 2020-03-04
ES2911910T3 (es) 2022-05-23
AU2016219253C1 (en) 2022-12-08
SG11201706515QA (en) 2017-09-28
UA122222C2 (uk) 2020-10-12
MX2017010363A (es) 2018-05-04
CA2976095C (en) 2023-10-17
WO2016130796A1 (en) 2016-08-18
BR112017017354A2 (pt) 2018-04-10
PT3256466T (pt) 2022-05-10

Similar Documents

Publication Publication Date Title
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
MX2020001157A (es) Compuestos y analogos de 1-heterociclil isocromanilo para el tratamiento de trastornos del sistema nervioso central (snc).
MX2020010690A (es) Oxiesteroles y metodos de uso de los mismos.
MX2023005098A (es) Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central.
MX2021004492A (es) Composiciones para el tratamiento de trastornos del snc.
MX2023002004A (es) Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
EP4316591A3 (en) Oxysterols and methods of use thereof
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
MX2016017030A (es) Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos.
MY202022A (en) Pyrrolotriazine compounds as tam inhibitors
MX2023001876A (es) Derivados de rapamicina.
PH12017501423A1 (en) Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders
TN2016000529A1 (en) Substituted dihydroisoquinolinone compounds
MX2020001832A (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre.
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
MX2022005024A (es) Profarmacos de fosforo de estimuladores de guanilato ciclasa soluble (sgc).
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.